UCL Cancer Institute  Immune Regulation and Tumour Immunotherapy
Group (IRTI)  Group Leader: Dr Sergio A Quezada PhD  Our group
uses transplantable and autochthonous mouse models of cancer to
investigate the in vivo interplay between the immune system and
cancer throughout tumour progression and immunotherapy. Our aim
to identify and target the most relevant cellular and molecular
pathways restricting the activation of tumour-reactive
lymphocytes, their access to the tumour site, and their activity
within the tumour microenvironment.   The use of our own immune
system to specifically target cancerous cells has become a
promising approach in the fight against cancer. However, anti-
tumour immunity is tightly regulated by cellular and molecular
circuits that prevent self and tumour destruction and
significantly limit the efficacy of existing therapies.   Fig 1
 The intra-tumour balance of effector and regulatory T cells:
The infiltration of tumours by different subsets of lymphocytes
can be initially affected b